Milestone (MIST) news
Recent news
Milestone Pharmaceuticals announces NMPA approval of Etripamil nasal spray for PSVT in China, marking first regulatory approval of Etripamil outside of the United States
Milestone Pharmaceuticals Inc. (Nasdaq: MIST) announced that the National Medical Products Administration (NMPA) in China has accepted the New Drug Application (NDA) for etripamil nasal spray for the treatment of paroxysmal supraventricular tachycardia (PSVT) . This marks the first regulatory…
AInvest Wire · Sep 3, 2026Everest Medicines - NMPA approves Cardamyst (Etripamil) NDA for PSVT in adults in China
Milestone Pharmaceuticals Inc. (Nasdaq: MIST) announced that Everest Medicines, its licensing partner in Greater China, has received approval from the National Medical Products Administration (NMPA) for the New Drug Application (NDA) of CARDAMYST™ (etripamil) nasal spray for the treatment of…
AInvest Wire · Sep 3, 2026ImportantMilestone Pharmaceuticals shares sank 28% after receiving rejection from FDA
Milestone Pharmaceuticals shares sank 28% after receiving rejection from FDA Milestone Pharmaceuticals, a biopharmaceutical company, announced the submission of a New Drug Application (NDA) to the U.S. Food and Drug Administration (FDA) for etripamil for the treatment of paroxysmal supraventricular…
AInvest Wire · Dec 26, 2023Milestone Pharma resumes trading, drops 41% premarket on FDA saying NDA, submitted in Oct. 2023 not sufficiently
AInvest Wire · Dec 26, 2023ImportantMIST: FDA says NDA, submitted in Oct. 2023 not suffieciently
MIST: FDA says NDA, submitted in Oct. 2023 not suffieciently The FDA has determined that an NDA, submitted in October 2023, was not sufficiently withdrawn from sale for reasons of safety or effectiveness. This determination means that the FDA will not begin procedures to withdraw approval of…
AInvest Wire · Dec 26, 2023Light Horse does not author, endorse or verify the headlines, and their appearance here is not an endorsement of any view they express.
This page is for informational purposes only. Nothing on it is a recommendation, solicitation or offer to buy or sell any security, nor investment, legal or tax advice. Light Horse Securities Inc does not verify third-party data and is not responsible for its accuracy, completeness or timeliness.